Physician profile
Christopher B Thomas
NPI 1033181821
$487.97
in general payments reported to CMS, 2019-2025
10 companies · $179 in 2025
The $179 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.21 · 2023: $42.21 · 2024: $231 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $452.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $134.13 | 2024 | Endurant Iis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.74 | 2025 | Jardiance |
| Abbott Laboratories | $68.53 | 2023-2025 | Viewmate, Fast-Cath, Brk |
| Pfizer INC. | $40.19 | 2019-2025 | |
| Amgen INC. | $28.74 | 2024 | Otezla, Repatha |
| Exact Sciences Corporation | $23.44 | 2024 | Cologuard Collection Kit |
| Vertex Pharmaceuticals Incorporated | $21.08 | 2024 | |
| Horizon Therapeutics Plc | $19.33 | 2023 | Krystexxa |
| Janssen Pharmaceuticals, INC | $17.47 | 2019 | |
| Glaxosmithkline, LLC. | $14.32 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.